| Drug Name |
Sevelamer hydrochloride |
| Drug ID |
BADD_D02014 |
| Description |
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel. |
| Indications and Usage |
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis. |
| Marketing Status |
approved |
| ATC Code |
V03AE02 |
| DrugBank ID |
DB00658
|
| KEGG ID |
D01983
|
| MeSH ID |
D000069603
|
| PubChem ID |
159247
|
| TTD Drug ID |
D03MZQ
|
| NDC Product Code |
72603-148; 62147-0077; 33342-241; 70748-173; 70748-172; 59651-087; 66499-0020; 59651-079; 76339-146; 59651-088; 68462-446; 68462-447; 58468-0021; 33342-242; 60687-449; 0955-1048; 59349-0017 |
| UNII |
GLS2PGI8QG
|
| Synonyms |
Sevelamer | GT335-012 | GT335 012 | GT335012 | Sevelamer Hydrochloride | Hydrochloride, Sevelamer | RenaGel | Sevelamer Carbonate | Carbonate, Sevelamer |